Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
SHANGHAI and HONG KONG, July 26, 2021 /PRNewswire/ -- In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics andUniversity of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, ...
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
SHANGHAI and HONG KONG, July 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
SHANGHAI and HONG KONG, July 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Provides an Update on Its Latest Developments
* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 monoclonal antibody, and ATG-027, a potential first-in-class B7H3/PD-L1 bi-specific antibody * Provides an update on commercial readiness across the Asia Pacific markets for selinexor, Antengene's f...
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 9, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics In...
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, May 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development
SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and...
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in he...
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onc...
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies
SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Today, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) successfully hosted an inauguration ceremony for its manufacturing center at the Binhai Life Science and Healthcare Industrial Zone in Shaoxing. The completion of the manufacturi...
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
SHANGHAI and HONG KONG, May 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolog...
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation ofthe Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of n...
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in h...
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onco...
